Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Points to Landscapes: Measuring and Scaling Up Methane Emissions From Mound-Building Termites.

Global change biology·2026
Same author

Re: Interpreting the cost-effectiveness of diabetes remission programmes beyond the durability of remission.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

<i>Supportive Care in What</i>? Myths and Misconceptions That Prevent the Provision of Excellent Cancer Care.

JCO global oncology·2026
Same author

Bridging prediction and reality: AI-based external validation of predictive models for lymph node metastasis in gastric cancer.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

"Am I too old for a shoulder replacement?" The association between age and comorbidities on the outcomes following Reverse Shoulder Arthroplasty.

Journal of shoulder and elbow surgery·2026
Same author

Evaluating a Train-the-Trainer program to implement a navigation program for older people with cancer across six European countries, as part of the EU NAVIGATE project: a Kirkpatrick multi-method evaluation.

BMC health services research·2026

Related Experiment Video

Updated: Apr 6, 2026

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.7K

Obinutuzumab in hematologic malignancies: lessons learned to date.

Tim Illidge1, Christian Klein2, Laurie H Sehn3

  • 1Institute of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

Cancer Treatment Reviews
|July 21, 2015
PubMed
Summary

Obinutuzumab, a type II anti-CD20 antibody, shows improved efficacy over rituximab in treating chronic lymphocytic leukemia (CLL) and non-Hodgkin

Keywords:
CD20CLLNHLObinutuzumabRituximabType II antibody

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K
Assessment of Human Natural Killer Cell Events Driven by Fc&#947;RIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

4.0K

Related Experiment Videos

Last Updated: Apr 6, 2026

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.7K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K
Assessment of Human Natural Killer Cell Events Driven by Fc&#947;RIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

4.0K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Anti-CD20 monoclonal antibodies (mAbs) have improved outcomes for CD20-positive non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
  • Despite rituximab's success, relapses remain common, necessitating more effective anti-CD20 mAbs.
  • Obinutuzumab is a unique type II glycoengineered anti-CD20 mAb with distinct mechanisms of action.

Purpose of the Study:

  • To evaluate the efficacy and mechanisms of action of obinutuzumab compared to type I anti-CD20 mAbs.
  • To assess obinutuzumab's potential in treating B-cell malignancies, including rituximab-refractory cases.

Main Methods:

  • Preclinical studies comparing obinutuzumab and rituximab in tumor models.
  • Clinical evaluation of obinutuzumab as monotherapy and in combination regimens.
  • A randomized phase III trial in untreated comorbid CLL patients comparing obinutuzumab plus chlorambucil versus rituximab plus chlorambucil.

Main Results:

  • Obinutuzumab demonstrated superior tumor remission in preclinical models and activity in rituximab-refractory tumors.
  • Obinutuzumab showed encouraging efficacy in NHL and CLL.
  • In the phase III CLL trial, obinutuzumab plus chlorambucil resulted in significantly higher overall response rates (78% vs. 65%) and longer progression-free survival (26.7 vs. 15.2 months) compared to rituximab plus chlorambucil.

Conclusions:

  • Obinutuzumab, a type II anti-CD20 antibody, offers distinct mechanisms and superior clinical outcomes compared to type I antibodies like rituximab in CLL.
  • Further trials are warranted to explore obinutuzumab's benefits across various CD20-positive B-cell malignancies.